Lv5
1110 积分 2025-12-01 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
4天前
已完结
GRPR‐Targeted Radionuclide Conjugates: A Molecular Evolution Perspective
12天前
已完结
GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy
12天前
已完结
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
25天前
已完结
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
25天前
已完结
Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial
1个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
3个月前
已关闭
Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review
3个月前
已完结
Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations
3个月前
已关闭
Guideline of guidelines: lutetium‐177 PSMA radioligand therapy in advanced prostate cancer
3个月前
已完结
皖公网安备34019202002308
